Evidence map›Paper›PMID 39323613›Full record

ArticleBleeding, thrombosis and vascular biology2024

Machine learning in cancer-associated thrombosis: hype or hope in untangling the clot.

Rushad Patell, Jeffrey I Zwicker, Rohan Singh, Simon Mantha

Abstract read
In one paragraph

Article in Bleeding, thrombosis and vascular biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Semi-Supervised Learning to Improve Generalizability of Cancer Associated-Venous Thromboembolism Risk Prediction Models.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rushad PatellDivision of Medical Oncology and Hematology, Beth Israel Deaconess Medical Center, Boston, MA.
Jeffrey I ZwickerDepartment of Medicine, Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Rohan SinghDepartment of Digital Informatics & Technology Solutions, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Simon ManthaDepartment of Medicine, Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Biomarkers and mechanisms in cancer associated thrombosisU01HL143365 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI CHAIKOF, ELLIOT, FLAUMENHAFT, ROBERT C · 2018 to 2022
$4.3M
Response to PQ12 - Using thiol isomerase inhibitors to diminish cancer induced thrombosisR21CA231000 · NCI · WESTERN NEW ENGLAND UNIVERSITY · PI KENNEDY, DANIEL ROBERT, PATELL, RUSHAD · 2019 to 2021
$377k
NCI NIH HHS P30 CA008748NCI NIH HHS R21 CA231000NHLBI NIH HHS U01 HL143365
6 · The paper itself

Abstract

The goal of machine learning (ML) is to create informative signals and useful tasks by leveraging large datasets to derive computational algorithms. ML has the potential to revolutionize the healthcare industry by boosting productivity, enhancing safe and effective patient care, and lightening the load on clinicians. In addition to gaining mechanistic insights into cancer-associated thrombosis (CAT), ML can be used to improve patient outcomes, streamline healthcare delivery, and spur innovation. Our review paper delves into the present and potential applications of this cutting-edge technology, encompassing three areas: i) computer vision-assisted diagnosis of thromboembolism from radiology data; ii) case detection from electronic health records using natural language processing; iii) algorithms for CAT prediction and risk stratification. The availability of large, well-annotated, high-quality datasets, overfitting, limited generalizability, the risk of propagating inherent bias, and a lack of transparency among patients and clinicians are among the challenges that must be overcome in order to effectively develop ML in the health sector. To guarantee that this powerful instrument can be utilized to maximize innovation in CAT, clinicians can collaborate with stakeholders such as computer scientists, regulatory bodies, and patient groups.

Indexed as

cancer-associated thrombosismachine learningnatural language processingvenous thromboembolism

Identifiers

PMID39323613
PMCPMC11423546

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.